Rybelsus? approved in Japan for the treatment of type 2 diabetes ... Read more


Novo Nordisk successfully completes AM833 phase 2 trial and phase 1 combination ... Read more


Novo Nordisk A/S – Share repurchase programme ... Read more


Novo Nordisk A/S – Share repurchase programme ... Read more


Novo Nordisk A/S – Share repurchase programme ... Read more


Rybelsus? approved in Japan for the treatment of type 2 diabetes ... Read more

Contact Media

If you have any queries please feel free to contact Media Relations at Novo Nordisk headquarters or one of our global offices.

Contact Media Relations
Press material is intended for media.


Novo Nordisk Media

Novo Nordisk launches new social responsibility strategy to defeat diabetes?

Defeat Diabetes

27 May -?At a time of acute global health need, Novo Nordisk today announced the launch of a new social responsibility strategy: ‘Defeat Diabetes’. The strategy strengthens Novo Nordisk’s commitment and introduces new long-term ambitions to provide access to affordable diabetes care to vulnerable patients in every country and to ensure that no child should die from type 1 diabetes.

“Our purpose to defeat diabetes is necessary now more than ever as diabetes continues to rise, and at a time when the world is suffering from the most devastating pandemic in recent times,” said Lars Fruergaard J?rgensen, CEO of Novo Nordisk. “In addition to innovative medicine, we are committed to help societies defeat diabetes by accelerating prevention to halt the rise of the disease and providing access to affordable care to vulnerable patients in every country. Vulnerability has many faces, and diabetes hits the hardest in vulnerable communities. I am proud that we are stepping up our efforts and working in partnerships to tackle the diabetes crisis at a time of profound need.”

Read more about Novo Nordisk's Defeat Diabetes strategy

Read the press release


Semaglutide 2.4mg demonstrates superior and sustained weight loss versus placebo and 17.4% weight loss after 68 weeks in STEP 4 trial

Mads Krogsgaard Thomsen, CSO


Bagsv?rd 13 May -?Novo Nordisk today announced headline results from STEP 4, the first completed phase 3a trial in the STEP programme. STEP 4 is a randomised, double-blind, multicentre, placebo-controlled, withdrawal trial exploring sustained weight management with semaglutide vs placebo. The 68-week trial investigated the effect of once-weekly subcutaneous (sc) semaglutide 2.4 mg on body weight in 902 people with obesity or overweight with comorbidities. After the 20-week run-in period, the 803 people reaching the target dose of semaglutide 2.4 mg had reduced their mean body weight from 107.2 kg to 96.1 kg and were randomised to continued treatment with either once-weekly sc semaglutide 2.4 mg or placebo for 48 weeks.

Read the full announcement


Financial results for first quarter of 2020

production Denmark

Novo Nordisk's sales increased by 16% in Danish kroner and by 14% at constant?exchange rates (CER) to DKK 33.9 billion in the first three months of 2020

Estimated sales growth adjusted for COVID-19-related stocking around 7% at CER

6 May 2020 - Lars Fruergaard J?rgensen, president and CEO comments on the financial results for the first three months of 2020: "Societies are severely impacted by the COVID-19 outbreak,?and during the pandemic our key priorities are to safeguard our employees, continue the supply of our life-saving?medicines and use our expertise, resources and global reach to help societies around the world during the?pandemic. COVID-19-related stocking impacted our results; however, we are satisfied with the underlying? commercial performance as well as the progression of our pipeline with the approval of Rybelsus ? in the EU and the?encouraging phase 2 data for semaglutide in NASH."

Read all the details in the announcement


Reliable supply of medicines

COVID-19 contributions

31 March?-?During the global coronavirus outbreak, Novo Nordisk’s key priority is to safeguard the continued supply of our lifesaving medicines to patients.

The situation is continually evolving, but currently we are not experiencing any supply constraints. We are well prepared for situations like this and have an inventory policy that serves long-term supply. This is important since our medicines are needed every day by patients all over the world.

Read Lars Fruergaard J?rgensen's perspective on how we are contributing to the fight against COVID-19

Updates on Novo Nordisk's latest contributions and initiatives


Novo Nordisk and UNICEF partner to help prevent childhood overweight and obesity

20 November -?Novo Nordisk and UNICEF have announced a new partnership to help prevent childhood overweight and obesity worldwide with an initial focus on interventions in Latin America and the Caribbean.

Under this partnership, the United Nations children’s agency and the global healthcare company will combine efforts to enhance knowledge and awareness on how to prevent overweight and obesity and address their root causes. The partnership will initially cover a period of three years.

“There is no doubt that childhood overweight and obesity is a public health crisis that requires immediate attention. Childhood overweight and obesity is more than an individual choice, this is everybody’s business. Together with UNICEF, we hope to help millions of children lead healthy lives and at the same time ease the burden of obesity to society,” said Novo Nordisk President and CEO Lars Fruergaard J?rgensen.

Read the full press release on the partnership

Read UNICEF's release


The technology behind tablets

production Denmark

What if medicines injected by millions could be delivered in tablets? After almost 100 years of delivering injectable therapies, Novo Nordisk’s R&D team is finding answers to this enduring question. Chief Science Officer Mads Krogsgaard Thomsen is leading the way and he reflects on the magnitude of the scientific challenge and the progress made in his laboratories.

Read Mads' reflections


Novo Nordisk to achieve target of 100% renewable power in production and launches new ambition aiming for zero environmental impact?

Circular for zero

Novo Nordisk intends to achieve the?target to use only renewable electricity in its global production facilities by 2020. The announcement on 30 April followed a new investment in a 672-acre solar panel installation, roughly the size of 500 football fields, in North Carolina, US, which will provide power to Novo Nordisk’s entire US operations from early 2020. Novo Nordisk is the first pharmaceutical company in RE100 to use only renewable electricity in production. RE100 is a collaborative, global initiative of businesses committed to using 100% renewable electricity.

Read more about?Circular for Zero?and download the full press release on the environmental ambitions?


Red Cross and Novo Nordisk partner to tackle chronic care in humanitarian crises

The International Committee of the Red Cross (ICRC), the Danish Red Cross (DRC) and Novo Nordisk have partnered to tackle the growing issue of chronic diseases that affect millions of people living in humanitarian crises around the world. Focus will be on ensuring efficient supply of low-cost human insulin in vials to Red Cross globally;?support for ICRC’s and DRC’s health programmes;?2-3 projects to provide care to people with hypertension and diabetes in humanitarian crises to be conducted within three years.

Read CEO Lars Fruergaard's reflections and more about the partnership



Financial Results, first quarter
06MayCopenhagen, Denmark

Annual Report 2019

Novo Nordisk in brief

Financial results 2020

6 May - first quarter

6 August - first 6 months

30 October - first 9 months


When Paris was diagnosed with type 1 diabetes at the age of two, his mother Wendy began filming. She didn’t stop for 16 years.?

Watch the documentary, 'Safely in the Rainbow', on YouTube